1) An (S)-enriched citalopram tartrate compound, wherein at least 70% of the citalopram moieties are the (S)-enantiomer of citalopram.
2) A process, which comprises treating a diastereomerically impure citalopram tartrate compound with formaldehyde to form an (S)-enriched citalopram tartrate compound.
3) Process, which comprises: resolving a citalopram tartrate compound in the presence of aqueous formaldehyde in one or more steps to form an (S)-enriched citalopram tartrate compound having at least 90% (S)-citalopram purity;
treating said (S)-enriched citalopram tartrate compound with base to form substantially (S)-citalopram; and optionally
reacting said substantially (S)-citalopram with oxalic acid to form (S)-citalopram oxalate.
Comments
Leave a comment